This Alnylam Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Avi Kapoor 2 months ago
MarketsTrading IdeasPre-Market OutlookNewsAnalyst RatingsInitiation
Top analysts change outlook on ALNY, AGMB, BMRN, BEKE, and IONS with ratings and price targets. Check out opinions and coverage on Benzinga.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- BMO Capital analyst David Lebowitz initiated coverage on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) with an Outperform rating and announced a price target of $318. Alnylam Pharmaceuticals closed at $228.61 on Tuesday. See how other analysts view this stock.
- Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage on Agomab Therapeutics NV (NASDAQ:AGMB) with an Overweight rating. AgomAb Therapeutics shares closed at $13.73 on Tuesday. See how other analysts view this stock.
- BMO Capital analyst David Lebowitz initiated coverage on Biomarin Pharmaceutical Inc (NASDAQ:BMRN) with an Outperform rating and announced a price target of $98. BioMarin Pharmaceutical closed at $66.99 on Tuesday. See how other analysts view this stock.
- CLSA analyst Alvin Huang initiated coverage on KE Holdings Inc – ADR (NYSE:BEKE) with an Outperform rating and announced a price target of $23.8. KE Holdings shares closed at $16.87 on Tuesday. See how other analysts view this stock.
- BMO Capital analyst David Lebowitz initiated coverage on Ionis Pharmaceuticals Inc (NASDAQ:IONS) with a Market Perform rating and announced a price target of $60. Ionis Pharmaceuticals closed at $59.62 on Tuesday. See how other analysts view this stock.
Considering buying ALNY stock? Here’s what analysts think:
Photo via Shutterstock